• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA clears IND for Cerveau’s tau imaging agent

June 16, 2017 By Sarah Faulkner

Cerveau TechnologiesCerveau Technologies said today that the FDA cleared the investigational new drug application for its tau imaging agent.

The company plans to work with pharmaceutical partners to evaluate the product’s use in positron emission tomography scans to assess neurofibrillary tangles in the brain. NFTs composed of aggregated tau protein are characteristic of certain neurodegenerative conditions like Alzheimer’s disease.

Cerveau holds a global license for the imaging agent from Merck (NYSE:MRK).

“We are pleased to reach this important milestone in the development of our novel, next-generation agent for the detection and quantitation of NFT in patients,” president Rick Hiatt said in prepared remarks. “We believe that it validates the faith our pharma partners have placed in us. Clinical studies will proceed to determine the ability of MK-6240 to stage disease and quantify the potential effects of therapeutic treatments for neurodegenerative disease, including Alzheimer’s disease. We are excited to work with our current collaborators as well as other partners to develop this agent as a potential biomarker for staging patients, and monitoring their therapy throughout treatment.”

Filed Under: Clinical Trials, Diagnostics, Featured, Food & Drug Administration (FDA), Neurological, Regulatory/Compliance Tagged With: Cerveau Technologies, Merck

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS